Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | PRKCG | P05129 | 1/20 | 0.35 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKCH | P24723 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11994572 | 1.00 | LMNA (0.46) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL26334858 | 0.87 | CYP2D6 (0.42) | LPAR3LPAR1LPAR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL17833014 | 0.87 | LMNA (0.58) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL13619237 | 0.87 | LMNA (0.58) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL26334849 | 0.87 | CYP2D6 (0.42) | LPAR3LPAR1LPAR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL26334850 | 0.87 | CYP2D6 (0.42) | LPAR3LPAR1LPAR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL26334857 | 0.85 | CYP2D6 (0.39) | LPAR3LPAR1LPAR2SMN1; SMN2 | |
| SCHEMBL1897610 | 0.84 | LMNA (0.67) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL16417850 | 0.82 | LPAR3 (0.47) | LPAR3LPAR1LPAR2 | |
| SCHEMBL14447944 | 0.82 | LMNA (0.59) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616140-B2 | Fluorescent phospholipid ether compounds, compositions, and methods of use | CELLECTAR BIOSCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150044142-A1 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CELLECTAR, INC. (US) | 2015-02-12 | — | — | US | disclosed |
| US-8871181-B2 | Fluorescent phospholipid ether compounds, compositions, and methods of use | CELLECTAR, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120128596-A1 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CELLECTAR, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20100286510-A1 | USE OF FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS IN BIOPSIES | CELL ACQUISITION CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100284931-A1 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CELL ACQUISITION CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100284930-A1 | FLUORESCENT IMAGING OF SKIN CANCERS USING PHOSPHOLIPID ETHER COMPOUNDS | CELL ACQUISITION CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100284929-A1 | FLUORESCENT IMAGING OF TUMORS USING PHOSPHOLIPID ETHER COMPOUNDS | CELL ACQUISITION CORP. | 2010-11-11 | — | — | US | disclosed |
| US-7811548-B1 | Fluorescent phospholipid ether compounds and compositions | CELLECTAR, INC. (US) | 2010-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044142-A1 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | PHOSPHO1, SGMS2, SGMS1 | LMNA 498/4885AKT1 3358/4885ESR1 1343/4885 |
| US-20100286510-A1 | USE OF FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS IN BIOPSIES | PHOSPHO1, SGMS2, SGMS1 | LMNA 530/4885AKT1 4070/4885ESR1 1146/4885 |
| US-20100284931-A1 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | PHOSPHO1, SGMS1, SGMS2 | LMNA 492/4885AKT1 2479/4885ESR1 888/4885 |
| US-20120128596-A1 | FLUORESCENT PHOSPHOLIPID ETHER COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | PHOSPHO1, SGMS1, SGMS2 | LMNA 449/4885AKT1 3420/4885ESR1 1349/4885 |
| US-20100284929-A1 | FLUORESCENT IMAGING OF TUMORS USING PHOSPHOLIPID ETHER COMPOUNDS | PHOSPHO1, PEBP1, SGMS1 | LMNA 1413/4885AKT1 2443/4885ESR1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.